Pharmacological management of behavioral symptoms associated with dementia  

作　　者：Subramoniam Madhusoodanan Mark Bryan Ting 

机构地区：[1]Department of Psychiatry, SUNY Downstate Medical Center, Brooklyn, NY 11203, United States [2]Department of Psychiatry, St. John’s Episcopal Hospital, Far Rockaway, NY 11691, United States

出　　处：《World Journal of Psychiatry》2014年第4期72-79,共8页世界精神病学杂志

摘　　要：Dementia is a clinical syndrome with features of neurocognitive decline. Subtypes of dementia include Alzheimer's, frontotemporal, Parkinson's, Lewy body disease, and vascular type. Dementia is associated with a variety of neuropsychiatric symptoms that may include agitation, psychosis, depression, and apathy. These symptoms can lead to dangerousness to self or others and are the main source for caregiver burnout. Treatment of these symptoms consists of nonpharmacological and pharmacological interventions. However, there are no Food and Drug Administration-approved medications for the treatment of behavioral and psychological symptoms of dementia. Pharmacological interventions are used off-label. This article reviews the current evidence supporting or negating the use of psychotropic medications along with safety concerns, monitoring, regulations, and recommendations.Dementia is a clinical syndrome with features of neurocognitive decline. Subtypes of dementia include Alzheimer's, frontotemporal, Parkinson's, Lewy body disease, and vascular type. Dementia is associated with a variety of neuropsychiatric symptoms that may include agitation, psychosis, depression, and apathy. These symptoms can lead to dangerousness to self or others and are the main source for caregiver burnout. Treatment of these symptoms consists of nonpharmacological and pharmacological interventions. However, there are no Food and Drug Administration-approved medications for the treatment of behavioral and psychological symptoms of dementia. Pharmacological interventions are used off-label. This article reviews the current evidence supporting or negating the use of psychotropic medications along with safety concerns, monitoring, regulations, and recommendations.

关 键 词：Alzheimer’s DISEASE DEMENTIA PHARMACOLOGICAL management PSYCHOTROPICS ANTIPSYCHOTICS 

分 类 号：R749.16[医药卫生—神经病学与精神病学]